Ghent University Academic Bibliography

Advanced

An adjuvanted polyprotein HIV-1 vaccine induces polyfunctional cross-reactive CD4+ T cell responses in seronegative volunteers

Eva Van Braeckel, Patricia Bourguignon, Marguerite Koutsoukos, Frédéric Clement UGent, Michel Janssens, Isabelle Carletti, Alix Collard, Marie-Ange Demoitié, Gerald Voss, Geert Leroux-Roels UGent, et al. (2011) CLINICAL INFECTIOUS DISEASES. 52(4). p.522-523
abstract
Background. This phase I/II partially blinded, randomized, dose-ranging study assessed the safety and immunogenicity of a novel human immunodeficiency virus type 1 (HIV-1) vaccine candidate consisting of a recombinant fusion protein (F4) containing 4 HIV-1 clade B antigens (Gag p24, Pol reverse transcriptase, Nef, and Gag p17) adjuvanted with AS01 in HIV-seronegative volunteers. Methods. Two doses of the recombinant F4 protein (10, 30, or 90 μg/dose), adjuvanted with AS01 or reconstituted with water for injection, were administered 1 month apart to 180 healthy volunteers aged 18-40 years. F4-specific CD4(+) T cell responses were measured using intracellular cytokine staining after in vitro stimulation by overlapping peptide pools covering the 4 individual antigens. Results. Reactogenicity was higher during the 7-day period after each vaccine dose in the adjuvanted than in the nonadjuvanted groups. In the adjuvanted groups, the overall immune response rate was high after the second vaccine dose, with highest responder rates seen in the 10-μg F4/AS01 group (100% to 3 HIV-1 antigens and 80% to all 4 HIV-1 antigens). High and long-lasting CD4(+) T cell frequencies were observed (up to a median value of 1.2% F4-specific CD4(+) T cells at day 44), with strongest responses directed against reverse transcriptase. Antigen-specific CD4(+) T cells exhibited a polyfunctional phenotype, expressing at least CD40 ligand and interleukin 2, often in combination with tumor necrosis factor α and/or interferon γ. Vaccine-induced CD4(+) T cell responses were broadly cross-reactive to all 4 antigens derived from HIV-1 clades A and C. Conclusions. These results support further clinical investigation of this HIV-1 vaccine candidate both in a prophylactic setting (alone, in conjunction with an envelope-based antigen or in combination with other vaccine approaches in a heterologous prime-boost regimen) and as a potentially disease-modifying therapeutic vaccine in HIV-1-infected subjects.
Please use this url to cite or link to this publication:
author
organization
alternative title
An adjuvanted polyprotein HIV-1 vaccine induces polyfunctional cross-reactive CD4(+) T cell responses in seronegative volunteers
year
type
journalArticle (original)
publication status
published
subject
keyword
TRIAL, SYSTEMS, MEMORY, INFECTION, PRECLINICAL EVALUATION, S/AS02A, ADULTS, DOUBLE-BLIND, EFFICACY, IMMUNOGENICITY, RTS
journal title
CLINICAL INFECTIOUS DISEASES
Clin. Infect. Dis.
volume
52
issue
4
pages
522 - 523
Web of Science type
Article
Web of Science id
000286677800019
JCR category
INFECTIOUS DISEASES
JCR impact factor
9.154 (2011)
JCR rank
2/70 (2011)
JCR quartile
1 (2011)
ISSN
1058-4838
DOI
10.1093/cid/ciq160
language
English
UGent publication?
yes
classification
A1
copyright statement
I have transferred the copyright for this publication to the publisher
id
1114576
handle
http://hdl.handle.net/1854/LU-1114576
date created
2011-02-02 09:57:58
date last changed
2016-12-19 15:45:26
@article{1114576,
  abstract     = {Background. This phase I/II partially blinded, randomized, dose-ranging study assessed the safety and immunogenicity of a novel human immunodeficiency virus type 1 (HIV-1) vaccine candidate consisting of a recombinant fusion protein (F4) containing 4 HIV-1 clade B antigens (Gag p24, Pol reverse transcriptase, Nef, and Gag p17) adjuvanted with AS01 in HIV-seronegative volunteers. Methods. Two doses of the recombinant F4 protein (10, 30, or 90 \ensuremath{\mu}g/dose), adjuvanted with AS01 or reconstituted with water for injection, were administered 1 month apart to 180 healthy volunteers aged 18-40 years. F4-specific CD4(+) T cell responses were measured using intracellular cytokine staining after in vitro stimulation by overlapping peptide pools covering the 4 individual antigens. Results. Reactogenicity was higher during the 7-day period after each vaccine dose in the adjuvanted than in the nonadjuvanted groups. In the adjuvanted groups, the overall immune response rate was high after the second vaccine dose, with highest responder rates seen in the 10-\ensuremath{\mu}g F4/AS01 group (100\% to 3 HIV-1 antigens and 80\% to all 4 HIV-1 antigens). High and long-lasting CD4(+) T cell frequencies were observed (up to a median value of 1.2\% F4-specific CD4(+) T cells at day 44), with strongest responses directed against reverse transcriptase. Antigen-specific CD4(+) T cells exhibited a polyfunctional phenotype, expressing at least CD40 ligand and interleukin 2, often in combination with tumor necrosis factor \ensuremath{\alpha} and/or interferon \ensuremath{\gamma}. Vaccine-induced CD4(+) T cell responses were broadly cross-reactive to all 4 antigens derived from HIV-1 clades A and C. Conclusions. These results support further clinical investigation of this HIV-1 vaccine candidate both in a prophylactic setting (alone, in conjunction with an envelope-based antigen or in combination with other vaccine approaches in a heterologous prime-boost regimen) and as a potentially disease-modifying therapeutic vaccine in HIV-1-infected subjects.},
  author       = {Van Braeckel, Eva and Bourguignon, Patricia and Koutsoukos, Marguerite and Clement, Fr{\'e}d{\'e}ric and Janssens, Michel and Carletti, Isabelle and Collard, Alix and Demoiti{\'e}, Marie-Ange and Voss, Gerald and Leroux-Roels, Geert and McNally, Lisa},
  issn         = {1058-4838},
  journal      = {CLINICAL INFECTIOUS DISEASES},
  keyword      = {TRIAL,SYSTEMS,MEMORY,INFECTION,PRECLINICAL EVALUATION,S/AS02A,ADULTS,DOUBLE-BLIND,EFFICACY,IMMUNOGENICITY,RTS},
  language     = {eng},
  number       = {4},
  pages        = {522--523},
  title        = {An adjuvanted polyprotein HIV-1 vaccine induces polyfunctional cross-reactive CD4+ T cell responses in seronegative volunteers},
  url          = {http://dx.doi.org/10.1093/cid/ciq160},
  volume       = {52},
  year         = {2011},
}

Chicago
VAN BRAECKEL, EVA, Patricia Bourguignon, Marguerite Koutsoukos, Frédéric Clement, Michel Janssens, Isabelle Carletti, Alix Collard, et al. 2011. “An Adjuvanted Polyprotein HIV-1 Vaccine Induces Polyfunctional Cross-reactive CD4+ T Cell Responses in Seronegative Volunteers.” Clinical Infectious Diseases 52 (4): 522–523.
APA
VAN BRAECKEL, E., Bourguignon, P., Koutsoukos, M., Clement, F., Janssens, M., Carletti, I., Collard, A., et al. (2011). An adjuvanted polyprotein HIV-1 vaccine induces polyfunctional cross-reactive CD4+ T cell responses in seronegative volunteers. CLINICAL INFECTIOUS DISEASES, 52(4), 522–523.
Vancouver
1.
VAN BRAECKEL E, Bourguignon P, Koutsoukos M, Clement F, Janssens M, Carletti I, et al. An adjuvanted polyprotein HIV-1 vaccine induces polyfunctional cross-reactive CD4+ T cell responses in seronegative volunteers. CLINICAL INFECTIOUS DISEASES. 2011;52(4):522–3.
MLA
VAN BRAECKEL, EVA, Patricia Bourguignon, Marguerite Koutsoukos, et al. “An Adjuvanted Polyprotein HIV-1 Vaccine Induces Polyfunctional Cross-reactive CD4+ T Cell Responses in Seronegative Volunteers.” CLINICAL INFECTIOUS DISEASES 52.4 (2011): 522–523. Print.